Vpx-Independent Lentiviral Transduction and shRNA-Mediated Protein Knock-Down in Monocyte-Derived Dendritic Cells

PLoS One. 2015 Jul 24;10(7):e0133651. doi: 10.1371/journal.pone.0133651. eCollection 2015.

Abstract

The function of dendritic cells (DCs) in the immune system is based on their ability to sense and present foreign antigens. Powerful tools to research DC function and to apply in cell-based immunotherapy are either silencing or overexpression of genes achieved by lentiviral transduction. To date, efficient lentiviral transduction of DCs or their monocyte derived counterparts (MDDCs) required high multiplicity of infection (MOI) or the exposure to the HIV-2/SIV protein Vpx to degrade viral restriction factor SAM domain and HD domain-containing protein 1 (SAMHD1). Here we present a Vpx-independent method for efficient (>95%) transduction of MDDCs at lower MOI. The protocol can be used both for ectopic gene expression and knock-down. Introducing shRNA targeting viral entry receptor CD4 and restriction factor SAMHD1 into MDDCs resulted in down-regulation of targeted proteins and, consequently, expected impact on HIV infection. This protocol for MDDCs transduction is robust and free of the potential risk arising from the use of Vpx which creates a virus infection-prone environment, potentially dangerous in clinical setting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dendritic Cells / immunology
  • Dendritic Cells / metabolism*
  • Gene Knockdown Techniques*
  • Genes, Reporter
  • Genetic Vectors / genetics*
  • HIV-1 / genetics
  • Humans
  • Lentivirus / genetics*
  • RNA, Small Interfering / genetics*
  • Transduction, Genetic*
  • Viral Regulatory and Accessory Proteins / metabolism*
  • Virus Replication / genetics

Substances

  • RNA, Small Interfering
  • VPX protein, Simian immunodeficiency virus
  • Viral Regulatory and Accessory Proteins

Grants and funding

The authors are supported by grants to BV from the Research Foundation—Flanders (FWO) and to BV, HN and HF from Ghent University (Geconcerteerde Onderzoeksactie BOF11/GOA/013). WW, JV and AL are PhD Fellows and BV is a Senior Clinical Investigator of the FWO.